Niet in de ether

Doorlopend verhaal · 1 reportage

Trump administration's ibogaine fast-track effort

Eerst uitgezonden Laatst uitgezonden

In ontwikkelingVolgende controle op : Whether the administration or FDA abandons the effort, or the FDA completes a decision on ibogaine’s development or approval pathway.

Stand van zaken

As of July 23, 2026, the Trump administration was pushing to fast-track ibogaine for addiction treatment, while experts cited cardiac risks linked to potentially fatal arrhythmias. The report identifies Trump and the FDA as decision-makers but gives no decision, next step or indication that the effort has been abandoned.

DossiervolgerDag 1

1 bericht11 media11 bronnen1 video

  • Nog geen gedateerde gebeurtenissen
    1. Update 1Twenty-Seven Dead, No FDA Approval, and a Presidential Pen

    Het verhaal tot nu toe

    1. Update 1

      Twenty-Seven Dead, No FDA Approval, and a Presidential Pen

      Trump's April executive order fast-tracks ibogaine, a Schedule I psychedelic with documented cardiac risk, while Americans keep dying at unregulated clinics abroad.

      Nog open na dit bericht

      • The full death toll at foreign clinics, including non-American patients, is not publicly tracked.
      • How the FDA will interpret "expedite" — whether it fast-tracks a specific application or reopens the research pathway — has not been disclosed.
      • Whether Texas's state-funded trials will produce randomized data sufficient for an FDA submission.

    Geschiedenis

    1. Geopend1 reportage

    Wie erbij betrokken is

    Personen

    • Céline GounderAmerican infectious disease physician, internist, epidemiologist, filmmaker, and medical journalist1 bericht
    • Donald TrumpPresident of the United States (2017–2021; since 2025)1 bericht
    • Joe RoganAmerican broadcaster, comedian, and actor (born 1967)1 bericht

    Plaatsen

    • MexicoMexico1 bericht
    • Stanford University450 Jane Stanford Way, Stanford, CA 94305, USA1 bericht
    • TexasTexas, USA1 bericht
    • The Oval Office1600 Pennsylvania Ave NW, Washington, DC 20500, USA1 bericht

    Alle media die we over dit dossier lazen

    11 bronnen11 media1 video